TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of “first-in-class” or “best-in-class” new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting conjugate molecule technology platform and a new drug R&D pipeline with global IP protection. Several products are currently in Phase II/III clinical trials targeting at diseases such as H. pylori infection, implanted medical device infections (e.g. prosthetic joint infection), acute bacterial skin and skin structure infections, liver cirrhosis hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to addressing the unmet medical needs in these disease areas and providing safe and effective therapies for patients in China and around the world.